| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 165,20 | 165,80 | 12:03 | |
| 165,00 | 165,80 | 11:54 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection | ||
| Mi | AbbVie wins FDA nod for a label expansion of Enanta-partnered antiviral | ||
| Mi | U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus | MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus... ► Artikel lesen | |
| Di | AbbVie auf Goldman Sachs Konferenz: Strategisches Wachstum und Innovation | ||
| Di | TV drug ad spending continued downward slope in May, with AbbVie's Skyrizi hanging on to top spot |
